Compare Global X Defense Tech ETF (SHLD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Defense Tech ETF vs TG Therapeutics Inc — how do they compare? Global X Defense Tech ETF trades at $60.24, while TG Therapeutics Inc trades at $54.06 (market cap $8.26B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals.
| SHLD | TGTX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $78.02 | $59.06 |
52-Week Low | $58.20 | $26.39 |
Market Cap | — | $8.26B |
Enterprise Value | — | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHLD trades at $60.03, down 0.05% on the day, with technical indicators showing a bearish trend from moving averages but neutral oscillators. The ETF focuses on global defense technology, benefiting from rising military budgets and geopolitical tensions. Recent news highlights institutional interest, including Decker Wealth Management's new position in Q1 2026, and analyst discussions on defense ETF comparisons amid sector tailwinds.
The outlook for SHLD is supported by structural growth in defense spending, but risks include political uncertainty and valuation concerns. Investors gain diversified exposure to defense tech innovation, though competition from other ETFs and expense ratios may impact relative performance. Near-term price action hinges on technical support at $59 and broader market sentiment toward defense stocks.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
